Who
Howard Berman
Director
Company insider
Files Form 4 as: Director, Atea Pharmaceuticals; Executive Chairman, Coya Therapeutics.
In numbers
- Trades disclosed
- 13
- Buys
- 1
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 3 Jan 2023
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,700 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,700 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,257 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,257 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | AVIR Atea Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —164,800 at $0.00 | filing |
| 9 Jan 2025filed 13 Jan 2025 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,602 at $0.00 | filing |
| 3 Jun 2024filed 5 Jun 2024 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —163,663 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —189,680 at $0.00 | filing |
| 27 Feb 2023filed 1 Mar 2023 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —165,000 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —5,000 | filing |
| 3 Jan 2023filed 4 Jan 2023 | COYA Coya TherapeuticsBiotechnology | SEC FORM 4 Bought | —10,000 | filing |
News
Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastCOYA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Howard Berman; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.